Effects ofPlasmodium berghei infection on cytochromes P-450 2E1 and 3A2

  • K. Uhl
  • J. M. Grace
  • D. A. Kocisko
  • B. T. Jennings
  • A. L. Mitchell
  • T. G. Brewer


Metabolism and disposition of most drugs used to treat malaria are substantially altered in malaria infection. Few data are available that specify effects of malaria infection on drug metabolism pathways in humans or animal model systems. In this report, studies were undertaken to determine the effect ofPlasmodium berghei infection on cytochrome P-450 (CYP450) 2E1 and 3A2-mediated metabolism and enzyme expression in rat liver microsomes. Malaria infection (MAL) resulted in significant decreases in total cytochrome P-450 content (56%,P<0.05) and NADPH cytochrome P-450 reductase activity (32%,P<0.05) as compared to control (CON) rats. Chlorzoxazone 4-hydroxylase activity (CYP2E1-mediated) showed no significant difference between CON and MAL microsomes while testosterone 6-\-hydroxylase activity (CYP3A2-mediated) was reduced by 41% (P<0.05) in MAL. Enzyme kinetic studies and immunoblot analysis indicate that the loss of activity for CYP3A2 in malaria infection is due to significantly decreased CYP3A2 protein expression. The altered expression of CYP450s in malaria infection should be taken into account when treating patients with malaria in order to minimize drug-drug interactions or toxicity.


Cytochrome P-450 liver microsomes Sprague-Dawley rats malaria Western blotting isozymes 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Oaks S.C., Mitchell V.S., Pearson G.W., Carpenter C.CJ. (eds) (1991): Malaria: Obstacles and Opportunities, A report of the committee for the study on malaria prevention and control: Status Review and Alternative Strategies. Division of International Health, Institute of Medicine, National Academy Press.Google Scholar
  2. 2.
    Na-Bangchang K., Limpaibul L. (1994): The pharmacokinetics of chloroquine in healthy Thai subjects and patients withPlasmodium vivax malaria. Br. J. Clin. Pharmacol., 38: 278–281.PubMedGoogle Scholar
  3. 3.
    White N.J., Looareesuwan S., Warrell D.A., Warrell M.J., Bunnag D., Harinasuta T. (1982). Quinine pharmacokinetics and toxicity in cerebral and uncomplicated falciparum malaria. Am. J. Med., 73: 564–571.CrossRefPubMedGoogle Scholar
  4. 4.
    White N.J. (1985): Clinical pharmacokinetics of antimalarial drugs. Clin. Pharmacokinet., 10: 187–215.CrossRefPubMedGoogle Scholar
  5. 5.
    Alvares A.P., Ueng T.H., Scheibel L.W., Hollingdale M.R. (1984): Impairment of hepatic cytochrome P-450 dependent monooxygenases by the malaria parasitePlasmodium berghei. Mol. Biochem. Parasitol., 13: 277–282.CrossRefPubMedGoogle Scholar
  6. 6.
    Glazier A.P., Kokwaro G.O., Edwards G. (1993): Possible isozyme-specific effects of experimental malaria withPlasmodium berghei on cytochrome P450 activity in rat liver microsomes. J. Pharm. Pharmacol., 46: 352–355.Google Scholar
  7. 7.
    Kokwaro G.O., Glazier A.P., Ward S.A., Breckenridge A.M., Edwards G. (1993): Effect of malaria infection and endotoxin-induced fever on phenacetin O-deethylation by rat liver microsomes. Biochem. Pharmacol., 45: 1235–1241.CrossRefPubMedGoogle Scholar
  8. 8.
    Mihaly G.W., Date N.M., Veenendaal J.R., Newman K.T., Smallwood R.A. (1987): Decreased hepatic elimination of pyrimethamine during malaria infection. Studies in the isolated perfused rat liver. Biochem. Pharmacol., 36: 2827–2829.CrossRefPubMedGoogle Scholar
  9. 9.
    Mansor S.M., Edwards G., Roberts PJ., Ward S.A. (1991): The effect of malaria infection on paracetamol disposition in the rat. Biochem. Pharmacol., 41: 1707–1711.CrossRefPubMedGoogle Scholar
  10. 10.
    Murdoch R.T., Ghabrial H., Smallwood R.A., Morgan DJ. (1992): Effect of malaria on phenol conjugation pathways in perfused rat liver. Biochem. Pharmacol., 43: 1229–1234.CrossRefPubMedGoogle Scholar
  11. 11.
    Black R.H., Ray A.P. (1977): Experimental studies of the potentiation of proguanil and pyrimethamine by dapsone usingPlasmodium berghei in white mice. Ann. Trop. Med. Parasitol., 71: 131–139.PubMedGoogle Scholar
  12. 12.
    Guengerich E.P. (1977): Separation and purification of multiple forms of microsomal cytochrome P-450: activities of different forms of cytochrome P-450 towards several compounds of environmental interest. J. Biol. Chem., 252: 3970–3979.PubMedGoogle Scholar
  13. 13.
    Lowry O.H., Rosenbrough N.J., Farr A.L., Randall R.J. (1951): Protein measurement with the Folin phenol reagent. J. Biol. Chem., 193: 265–275.PubMedGoogle Scholar
  14. 14.
    Omura T., Sato R.J. (1964): The carbon-monoxide-binding pigment of liver microsomes. J. Biol. Chem., 239: 2370–2378.PubMedGoogle Scholar
  15. 15.
    Phillips A.H., Langdon R.G. (1962): Hepatic triphosphopyridine nucleotide-cytochrome c reductase: isolation, characterization, and kinetic studies. J. Biol. Chem., 237: 2652–2660.PubMedGoogle Scholar
  16. 16.
    Peter R., Bocker R.G., Beaune P.H., Iwasaki M., Guengerich F.P., Yang C.S. (1990): Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450 IIE1. Chem. Res. Toxicol., 3: 566–573.CrossRefPubMedGoogle Scholar
  17. 17.
    Sonderfan AJ., Arlotto M.P., Dutton D.R., McMillen S.K., Parkinson A. (1987): Regulation of testosterone hydroxylation by rat liver microsomal cytochrome P-450. Arch. Biochem. Biophys, 255: 27–41.CrossRefPubMedGoogle Scholar
  18. 18.
    Rosen S., Royeroft D.W., Hans J.E., Barry K.G. (1967): The liver in malaria. Arch. Pathol., 83: 271–277.PubMedGoogle Scholar
  19. 19.
    Kokwaro G.O., Ismail S., Glazier A.P., Ward S.A., Edwards G. (1993): Effect of malaria infection and endotoxin-induced fever on the metabolism of antipyrine and metronidazole in the rat. Biochem. Pharmacol., 45: 1243–1249.CrossRefPubMedGoogle Scholar
  20. 20.
    Kokwaro G.O., Szwandt I.S.F., Glazier A.P., Ward S.A., Edwards G. (1993): Metabolism of caffeine and theophylline in rats with malaria and endotoxin-induced fever. Xeniobiotica, 23: 1391–1397.CrossRefGoogle Scholar
  21. 21.
    Adedayo A., Ams P.A., Richards W.O., Wilkinson G.R., Branch R.A. (1998): Selective effect of liver disease on the activities of specific metabolizing enzymes: Investigation of cytochromes P450 2C19 and 2D6. Clin. Pharmacol. Ther., 64: 8–17.CrossRefGoogle Scholar
  22. 22.
    Nebert D.W., McKinnon R.A., Puga A. (1996): Human drugmetabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. DNA Cell Biol., 15: 273–280.CrossRefPubMedGoogle Scholar
  23. 23.
    White NJ. (1985): Clinical pharmacokinetics of antimalarial drugs. Clin. Pharm., 10: 187–215.CrossRefGoogle Scholar
  24. 24.
    Chang K.C., Lauer B.A., Bell T.D., Chai H. (1978): Altered theophylline pharmacokinetics during acute respiratory viral illness. Lancet, 1: 1132–1133.CrossRefPubMedGoogle Scholar
  25. 25.
    Renton K.W., Gray J.D., Hall R.I. (1980): Decreased elimination of theophylline after influenza vaccination. Can. Med. Assoc. J., 123: 288–290.PubMedGoogle Scholar
  26. 26.
    Renton K.W. (1981): Effects of infection and immune stimulation on theophylline metabolism. Semin. Perinatol., 5: 378–382.PubMedGoogle Scholar
  27. 27.
    Renton K.W., Mannering G.J. (1976): Depression of hepatic cytochrome P-450-dependent monooxygenase systems with administered interferon inducing agents. Biochem. Biophys. Res. Commun., 73: 343–348.CrossRefPubMedGoogle Scholar
  28. 28.
    Chen Y.L., Florentin I., Batt A.M., Ferrari L., Giroud J.P., Chauvelot-Moachon L. (1992): Effect of interleukin-6 on cytochrome P450-dependent mixed-function oxidases in the rat. Biochem. Pharmacol., 44: 137–149.CrossRefPubMedGoogle Scholar
  29. 29.
    Shedlodsky S.I., Swim A.T., Robinson J.M., Gallicchio V.S., Cohen D.A., McClain C.J. (1987): Interleukin-1 (IL-1) depresses cytochrome P450 levels and activities in mice. Life Sci, 40: 2331–2336.CrossRefGoogle Scholar
  30. 30.
    Cribb A.E., Renton K.W. (1993): Dissociation of xanthine oxidase induction and cytochrome P450 depression during interferon induction in the rat. Biochem. Pharmacol., 46: 2114–2117.CrossRefPubMedGoogle Scholar
  31. 31.
    Morgan E.T. (1997): Regulation of cytochromes P450 during inflammation and infection. Drug. Metab. Rev., 29: 1129–1188.CrossRefPubMedGoogle Scholar
  32. 32.
    Chung H., Brown D.R. (1976): The mechanism of the effect of acute stress on hexobarbital metabolism. Toxicol. Appl. Pharmacol., 37: 313–318.CrossRefPubMedGoogle Scholar
  33. 33.
    Bissell D.M., Hammaker L.E. (1976): Cytochrome P-450 heme and the regulation of delta-aminolevulinic acid synthetase in the liver. Arch. Biochem. Biophys., 176: 103–112.CrossRefPubMedGoogle Scholar
  34. 34.
    Koizumi A., Hasegawa L., Rodgers K.E., Ellefson D., Walford R., Imamura T. (1986): Influence of H-2 haplotypes on poly IC induction of xanthine oxidase and poly IC induced decreases in P-450 mediated enzyme activities. Biochem. Biophys. Res. Commun., 138: 246–253. T. (1996): Endotoxemia in rats is associated with induction ofCrossRefPubMedGoogle Scholar
  35. 35.
    Wink D.A., Osawa Y., Darbyshire J.F., Jones C.R., Eshenaur S.C., Nims R.W. (1993): Inhibition of cytochromes P450 by nitric oxide and a nitric oxide-releasing agent. Arch. Biochem. Biophys., 300: 115–123.CrossRefPubMedGoogle Scholar
  36. 36.
    Ryan D.E., Thomas P.E., Reik L.M., Levin W. (1982): Purification, characterization and regulation of five rat hepatic microsomal cytochrome P-450 isozymes. Xenobiotica, 12: 727–744.CrossRefPubMedGoogle Scholar
  37. 37.
    Sewer M.B., Koop D.R., Morgan E the P4504A subfamily and suppression of several other forms of cytochrome P450. Drug Metab. Dispos., 24: 401-407.Google Scholar
  38. 38.
    Sakai H., Okamoto T., Kikkawa J. (1992): Suppression of hepatic drug metabolism by the interferon inducer, polyriboinosinic acid: polyribocitidylic acid. J. Pharmacol. Exp. Ther., 263: 381–386.PubMedGoogle Scholar
  39. 39.
    Singh G., Renton K.W. (1984): Inhibition of the synthesis of hepatic cytochrome P-450 by the interferon-inducing agent poly rI.rCi. Can. J. Physiol. Pharmacol., 69: 379–383.Google Scholar
  40. 40.
    Moochhala A.M., Renton K.W. (1989): The effect of IFN-alpha-Con1 on hepatic cytochrome P-450 and protein synthesis and degradation in hepatic microsomes. Int. J. Immunopharmacol., 13: 903–912.CrossRefGoogle Scholar
  41. 41.
    Cribb A.E., Delaporte E., Kim S.G., Novak R.F., Renton K.W. (1994): Regulation of cytochrome P-4501A and cytochrome P-4502E induction in the rat during the production of interferon alpha/beta. J. Pharmacol. Exp. Ther., 268: 487–494.PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1999

Authors and Affiliations

  • K. Uhl
    • 1
  • J. M. Grace
    • 1
  • D. A. Kocisko
    • 1
  • B. T. Jennings
    • 1
  • A. L. Mitchell
    • 1
  • T. G. Brewer
    • 2
  1. 1.Department of PharmacologyWalter Reed Army Institute of ResearchWashington, DCUSA
  2. 2.Armed Forces Research Institute of Medical ScienceBangkokThailand

Personalised recommendations